COMFORT-1 and joy for Incyte/Novartis' JAK inhibitor
This article was originally published in Scrip
Incyte will file for approval of its leading oral dual JAK inhibitor INCB18424 (ruxolitinib/INC424) for myelofibrosis in the US in the second quarter of 2011, based on highly promising results from its first Phase III study, COMFORT-1. It hopes the drug will become the first FDA-approved drug to treat the debilitating symptoms of the disease.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.